Bexson Biomedical Inc.
Private Company
Company Overview
Bexson Biomedical Inc. is developing a unique formulation of ketamine for chronic and acute pain disorders. The company's lead project is a novel ketamine delivery system that includes a proprietary formulation of ketamine delivered by a minimally invasive, wearable, subcutaneous infusion pump.
In February 2019, the company was granted Orphan Status for ketamine in the treatment of Complex Regional Pain Syndrome—its lead indication. In parallel, the company is targeting post operative pain management and other large market indications.
In February 2019, the company was granted Orphan Status for ketamine in the treatment of Complex Regional Pain Syndrome—its lead indication. In parallel, the company is targeting post operative pain management and other large market indications.
Management Team
Gregg Peterson
Chief Executive Officer
Jeffrey Becker, MD
Chief Science Officer
Mark Wiederhold, MD, Ph.D.
VP of Research & Development
Jason Wallach, Ph.D.
Director Bexon Discovery